1.60
+0.08(+5.26%)
Currency In USD
| Previous Close | 1.52 |
| Open | 1.52 |
| Day High | 1.61 |
| Day Low | 1.46 |
| 52-Week High | 16.94 |
| 52-Week Low | 1.46 |
| Volume | 144,386 |
| Average Volume | 314,932 |
| Market Cap | 41.86M |
| PE | -0.19 |
| EPS | -8.52 |
| Moving Average 50 Days | 2.13 |
| Moving Average 200 Days | 3.27 |
| Change | 0.08 |
If you invested $1000 in Senti Biosciences, Inc. (SNTI) since IPO date, it would be worth $16.03 as of August 18, 2025 at a share price of $1.6. Whereas If you bought $1000 worth of Senti Biosciences, Inc. (SNTI) shares 3 years ago, it would be worth $80.4 as of August 18, 2025 at a share price of $1.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
GlobeNewswire Inc.
Aug 14, 2025 1:15 PM GMT
Live video webcast on Tuesday, August 19th at 2:20 PM ETSOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and
Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia
GlobeNewswire Inc.
Aug 12, 2025 1:15 PM GMT
Access the “What This Means” segment here SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia
GlobeNewswire Inc.
Aug 05, 2025 12:30 PM GMT
Continued progress positions Company to report topline data for Phase 1 clinical trial of SENTI-202 before year-endSOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage